The Health Research Authority (HRA) has launched a new service offered to pharmaceutical companies and research organisations which will accelerate the ethics review stage of clinical trials approval.
The HRA will offer the new swift review to global trials and first-in-human studies that are developing medicines in ‘key areas of patient need’ including heart disease and diabetes.
The service will run in pilot form for the next three months, offering researchers a 75% reduction on the statutory timeline for ethics review.
